Alvotech (ALVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alvotech (ALVO) has a cash flow conversion efficiency ratio of 0.314x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Ikr-55.58 Million ≈ $-453.08K USD) by net assets (Ikr-176.76 Million ≈ $-1.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ALVO market cap for the company's overall valuation and market capitalisation.
Alvotech - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Alvotech's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alvotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alvotech ranked by their cash flow conversion efficiency. Explore earnings quality score of Alvotech to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Yanmade Technology Inc
SHG:688312
|
0.022x |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
0.015x |
|
Norbit ASA
OL:NORBT
|
-0.002x |
|
WEIBO CORP. A
F:2WB
|
N/A |
|
Naruida Technology Co. Ltd. Cl A
SHG:688522
|
N/A |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
0.044x |
|
Bombay Burmah Trading Corporation Limited
NSE:BBTC
|
0.039x |
|
Jupiter Wagons Limited
NSE:JWL
|
-0.041x |
Annual Cash Flow Conversion Efficiency for Alvotech (2020–2024)
The table below shows the annual cash flow conversion efficiency of Alvotech from 2020 to 2024. View Alvotech (ALVO) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Ikr-412.77 Million ≈ $-3.37 Million |
Ikr-236.84 Million ≈ $-1.93 Million |
0.574x | +71.39% |
| 2023-12-31 | Ikr-932.49 Million ≈ $-7.60 Million |
Ikr-312.19 Million ≈ $-2.55 Million |
0.335x | -39.51% |
| 2022-12-31 | Ikr-564.42 Million ≈ $-4.60 Million |
Ikr-312.39 Million ≈ $-2.55 Million |
0.553x | -67.10% |
| 2021-12-31 | Ikr-135.61 Million ≈ $-1.11 Million |
Ikr-228.17 Million ≈ $-1.86 Million |
1.683x | +1864.00% |
| 2020-12-31 | Ikr-867.24 Million ≈ $-7.07 Million |
Ikr-74.30 Million ≈ $-605.70K |
0.086x | -- |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more